LungLife AI has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.
Number of AIM securities in issue: 25,485,982 shares are issued, called up and fully paid. The Company holds no shares in treasury. This figure should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
|Significant shareholders||No of Common Shares||% of share capital|
|Icahn School of Medicine at Mount Sinai||2,469,842||9.7|
|Octopus Investments Ltd||1,968,750||7.7|
|Unicorn Asset Management||1,750,000||6.9|
|New Legacy Group||1,673,668||6.6|
|Frederick W Gluck||1,530,596||6.0|
|Stifel Nicolaus & Co||1,448,784||5.7|
|Investec Wealth & Management||1,408,727||5.5|
|Livzon Pharmaceutical Group Inc||1,347,653||5.3|
|Lombard Odier Asset Mgt||1,268,363||5.0|
|Accord Data Holdings||954,048||3.7|
|Killik Asset Mgt||912,632||3.6|
|Director||No of Common Shares||% of share capital|
Percentage of securities not in public hands: As of 31 August 2023 the percentage of common shares not in the public hands was 49.4%.
There are no restrictions on the transfer of the Company’s common shares.
LungLife AI is not subject to the City Code because its registered office is outside the UK, the Channel Islands and the Isle of Man. As a result, certain of the protections that are afforded to shareholders under the City Code, for example in relation to a takeover of a company or certain stakebuilding activities by shareholders, do not apply to LungLife AI. Certain provisions have been inserted into LungLife AI’s Certificate of Incorporation that adopt similar procedures to the City Code in the event of any party (or parties acting in concert) obtaining 30 per cent or more of the voting rights attaching to the issued Ordinary Shares, but there is no assurance that the courts of Delaware will uphold or allow the enforcement of these provisions.
This page was last updated on: 31 August 2023